This article was originally published in The Tan Sheet
J&J agrees to settle shareholder complaint; USPlabs destroys DMAA product; Acura strengthens Nexafed; Abbott nutrition sales drive growth; Re-launches drive Novartis OTC rebound; more news In Brief.
You may also be interested in...
GNC Supply Chain Reform Pays Dividends In DoJ Settlement From DMAA Investigation
DoJ announces a "non-prosecution agreement" that requires GNC to pay $2.25m and to cooperate in dietary supplement market investigations conducted by FDA and other federal agencies, including the current litigation against USPlabs.
Consent Decree Orders FDA Action On Triclosan OTC Monographs
A Nov. 21 consent decree sets multiple deadlines over a five-year period to make FDA finalize its OTC topical antimicrobial drug products monograph with respect to triclosan. Under a pair of deadlines of note to triclosan product makers, the agency must publish a tentative final monograph for consumer antiseptic hand-wash products by Dec. 16, with a final monograph due Sept. 15, 2016.
FDA seeks DMAA product seizure; skin tag remover study flawed – ERSP; Plan B One-Step approved fully OTC; FDA continues evaluating laxative TEA; FDA hosts supply chain public hearing; energy drink marketing to youths challenged; more news In Brief.